Evaluation of Pioglitazone Vildagliptin Combination on Lipid Profiles for Outpatients with Type II Diabetes Mellitus

Yunita Dyah Kusumaningrum; Adelia Firandi; Didik Hasmono; Dhita Aryani; Firdha Aprillia Wardhani

doi:10.35451/jfm.v7i2.2645

Authors

Yunita Dyah Kusumaningrum Universitas Jember
Adelia Firandi Universitas Jember
Didik Hasmono Universitas Airlangga
Dhita Aryani Universitas Jember
Firdha Aprillia Wardhani

DOI:

https://doi.org/10.35451/jfm.v7i2.2645

Keywords:

antidiabetes, DM tipe II, lipid profile, effectiveness of therapy

Abstract

Pioglitazone and vildagliptin combination is one of the recommended alternatives as antidiabetic therapy to achieve the therapeutic target. This combination with complementary mechanisms of action can improve lipid profiles. This study aims to evaluate lipid profile achievement for outpatients with Type II DM on administering pioglitazone/vildagliptin combination therapy. Methods of the study were an observational prospective study in outpatients with Type II DM who use pioglitazone/vildagliptin combination at RS. Bhayangkara Surabaya during November 2021 – April 2022. Patients were included if aged between 18-80 y.o, used this combination ? 3 months before the study, HbA1C >7%, and were voluntarily involved by signing the informed consent. Laboratory examination of HbA1c, HDL-C, and triglycerides was done initially when patients were voluntarily involved as baseline data and after 3 months as post-data. The final sample in this study consisted of 25 patients who met the inclusion and exclusion criteria. The results of the study show mean value of HDL-C significantly increases from baseline to endpoint (p < 0.05). At the end of 3 months, the lipid profile of HDL-C and triglyceride increases by 30% and 4%, respectively, in patients who achieve the target compared to baseline conditions. The combination therapy of pioglitazone and vildagliptin improved lipid profile control in patients with type 2 diabetes mellitus after 3 months of treatment.

Downloads

Download data is not yet available.

References

Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. doi:10.1016/j.diabres.2021.109119.

Lin X, Xu Y, Pan X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020;10:14790. doi:10.1038/s41598-020-71908-9

Khin PP, Lee JH, Jun HS. Pancreatic beta-cell dysfunction in type 2 diabetes. Eur J Inflamm. 2023;21:1721727X231154152. doi:10.1177/1721727X231154152

Galicia-Garcia U, Benito-Vicente A, Jebari S, et al. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020;21(17):6275–6309. doi:10.3390/ijms21176275

Trujillo J, Haines S. Diabetes Mellitus. In: DiPiro JT, Yee GC, Haines ST, Nolin TD, Ellingrod VL, Posey L, editors. DiPiro's Pharmacotherapy: A Pathophysiologic Approach. 12th ed. New York: McGraw Hill; 2023. p. 1–10.

Suprapti B, Izzah Z, Anjani AG, Andarsari MR, Nilamsari WP, Nugroho CW. Prevalence of medication adherence and glycemic control among patients with type 2 diabetes and influencing factors: A cross-sectional study. Glob Epidemiol. 2023;5:100113. doi:10.1016/j.gloepi.2023.100113.

Ningrum VDA, Sadewa AH, Ikawati Z, Yuliwulandari R, Ikhsan MR, Fajriyah R. The influence of metformin transporter gene SLC22A1 and SLC47A1 variants on steady-state pharmacokinetics and glycemic response. PLoS One. 2022;17(7):e0271410.

Perkeni. Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia 2021. Jakarta: Perkeni; 2021. p. 1–95.

American Diabetes Association (ADA). Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;43(1):1–212.

Mosenzon O, Alguwaihes A, Leon JLA, Bayram F, Darmon P, Davis TME, et al. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol. 2021;20(1):154. doi:10.1186/s12933-021-01344-0.

Kaur M, Rai J, Bal B, Kaur J. The impact of three combinations vildagliptin/metformin, vildagliptin/pioglitazone, and metformin/pioglitazone on glycemic control and atherogenic dyslipidemia in patients with Type 2 diabetes mellitus. Int J Basic Clin Pharmacol. 2014;3(5):903.

International Diabetes Federation (IDF). IDF Diabetes Atlas: Tenth edition 2021. Brussels, Belgium: International Diabetes Federation; 2021 [cited 2025 Mar 26]. Available from: https://www.diabetesatlas.org/en/resources/

Meirita E, Sari A. Evaluation of antibiotics usage rationality on diabetes mellitus type II patients at inpatient installation of Grandmed Hospital Lubuk Pakam in 2022. J Farmasimed (JFM). 2022;5(1):73–79. doi:10.35451/jfm.v5i1.1314.

Afifah H, Dewi IP, Rachmawati E, Holidah D, Norcahyanti I. Drug interaction study in type 2 diabetes mellitus with hypertension patients at X Hospital, Jember Regency. J Farmasimed (JFM). 2024;6(2):131–141. doi:10.35451/jfm.v6i2.2051.

Abdul-Ghani M, DeFronzo RA. Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?. Expert Opin Pharmacother. 2021;22(16):2113–25. doi:10.1080/14656566.2021.1967319.

Kim JH, Park JH, Lee YS, et al. Efficacy and safety of alogliptin-pioglitazone combination therapy versus monotherapy in patients with type 2 diabetes: A randomized controlled trial. Diabetes Metab J. 2023;47(1):45-56. doi:10.4093/dmj.2023.0259.

Lee SH, Kim SS, Cho YH, et al. Effects of adding pioglitazone to dapagliflozin and metformin therapy on lipid profiles and glycemic control in patients with type 2 diabetes: A 24-week study. Diabetes Metab J. 2023;47(2):78-89. doi:10.4093/dmj.2023.0314.

Tahir A, Martinez PJ, Ahmad F, et al. An evaluation of lipid profile and pro-inflammatory cytokines as determinants of cardiovascular disease in those with diabetes: a study on a Mexican American cohort. Sci Rep. 2021;11:2435. doi:10.1038/s41598-021-81730-6

Zhu Y, Yao T, Tian L, Zhang Y, Ke Q. Associations of triglyceride glucose-body mass index and the combination of sedentary behavior and physical activity with risks of all-cause mortality and myocardial infarction: a cohort study from the UK biobank. Cardiovasc Diabetol. 2025 Mar 1;24(1):102. doi:10.1186/s12933-025-02652-5.

Lorenzatti A, Toth P. New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease. Eur Cardiol Rev. 2020;15:e04. doi:10.15420/ecr.2019.06